These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6147642)

  • 1. Low-dose aminoglutethimide in treatment of advanced breast cancer.
    Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
    Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; Smith IE
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate SL
    Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate S
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
    Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
    Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
    Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
    Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglutethimide in the treatment of advanced breast cancer.
    Stuart-Harris RC; Smith IE
    Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038
    [No Abstract]   [Full Text] [Related]  

  • 9. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
    Lønning PE; Kvinnsland S; Thorsen T; Ueland PM
    Clin Pharmacokinet; 1987 Dec; 13(6):393-406. PubMed ID: 3436111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
    Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
    Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
    Bruning PF; Bonfrer JM; Hart AA; van der Linden E; de Jong-Bakker M; Moolenaar AJ; Nooijen WJ
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
    Harris AL
    Exp Cell Biol; 1985; 53(1):1-8. PubMed ID: 3881300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminoglutethimide therapy in advanced breast cancer.
    Anderson JL; Phillipou G; Black RB
    Aust N Z J Surg; 1981 Feb; 51(1):20-2. PubMed ID: 7013749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
    Dowsett M; Mehta A; Cantwell BM; Harris AL
    Eur J Cancer; 1991; 27(7):846-9. PubMed ID: 1657077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of aminoglutethimide in male breast cancer.
    Harris AL; Dowsett M; Stuart-Harris R; Smith IE
    Br J Cancer; 1986 Oct; 54(4):657-60. PubMed ID: 3778807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
    Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
    Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
    Samojlik E; Santen RJ; Wells SA
    J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
    [No Abstract]   [Full Text] [Related]  

  • 19. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
    J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience.
    Murray RM; Pitt P
    Cancer Res; 1982 Aug; 42(8 Suppl):3437s-3441s. PubMed ID: 6211229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.